To minimize side effects, we start with a low dose and gradually increase it based on your response and the latest clinical guidelines
Wegovy Wegovy is marketed as a weight loss drug for chronic weight management for adults to treat obesity
(Sitagliptin is a DPP-4 inhibitor, not a GLP-1 agonist, shown here for context as an alternative incretin-based therapy.) As seen, the trend was moving toward longer-acting, more convenient formulations without sacrificing efficacy
Your doctor can assess whether additional investigations are needed, such as breath tests for SIBO or H
The presence of GLP-1 receptors in the central nervous system, particularly in the ventral tegmental area (VTA) and nucleus accumbens (NAc), suggests their involvement in reward processing and motivation
While gallstone risk cannot be entirely eliminated, strategies that may help include following the prescribed gradual dose titration schedule, maintaining adequate dietary fat intake with meals, aiming for gradual rather than rapid weight loss, and attending regular follow-up appointments for symptom monitoring
